- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Relapsed or refractory multiple myeloma (RRMM)
- Meeting Date: July 2024
- Public Summary Document (PSD) July 2024 PBAC Meeting - (PDF 1.3MB)
- Public Summary Document (PSD) July 2024 PBAC Meeting - (Word 1.5MB)
Elranatamab – July 2024
Elranatamab; Solution for subcutaneous injection 44 mg in 1.1 mL (40 mg per mL), Solution for subcutaneous injection 76 mg in 1.9 mL (40 mg per mL); Elrexfio®
Last updated
30 May 2025